Medicus Pharma Ltd (TSE:MDCX) has released an update.
Medicus Pharma Ltd. has announced FDA feedback on their Phase 2 protocol for a non-invasive treatment for basal cell carcinoma, with the FDA requesting additional data on dosing and safety from prior studies. The treatment involves micro-array needles containing doxorubicin, and the upcoming study will compare two dosage levels against a placebo in a double-blinded trial with 60 participants. Previous Phase 1 trials have shown the treatment to be safe and tolerable, with promising efficacy results.
For further insights into TSE:MDCX stock, check out TipRanks’ Stock Analysis page.
